Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMT504 Phase 1 in Healthy Volunteers
NCT06312423Phase 1Recruiting
- Sponsor
- Ministry of Public Health of the Province of La Rioja
- Start
- Feb 2024
- Primary completion
- Aug 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of IMT504 in chronic pain and complex regional pain syndrome (CRPS) (3 arms), sponsored by Ministry of Public Health of the Province of La Rioja. Primary endpoints: Local and systemic reaction after administration at Day 28, Serious adverse event and 2 more. Started Feb 2024; status: recruiting.
02
Drugs
IMT504
03
Conditions
chronic paincomplex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on NCT06312423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312423.